Country: Canada
Language: English
Source: Health Canada
CALCIPOTRIOL (CALCIPOTRIOL MONOHYDRATE); BETAMETHASONE (BETAMETHASONE DIPROPIONATE)
TARO PHARMACEUTICALS INC
D05AX52
CALCIPOTRIOL, COMBINATIONS
50MCG; 0.5MG
GEL
CALCIPOTRIOL (CALCIPOTRIOL MONOHYDRATE) 50MCG; BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.5MG
TOPICAL
15G/50G
Prescription
Active ingredient group (AIG) number: 0252270002; AHFS:
APPROVED
2022-02-10
_ _ _Taro-Calcipotriol / Betamethasone Gel _ _ _ _ _ _ _ _ _ _ _ _Page 1 of 45 _ PRODUCT MONOGRAPH PR TARO-CALCIPOTRIOL / BETAMETHASONE GEL calcipotriol and betamethasone dipropionate gel 50 mcg/g calcipotriol (as monohydrate) and 0.5 mg/g betamethasone (as dipropionate) gel Topical Antipsoriatic Agent Vitamin D Analogue / Corticosteroid Taro Pharmaceuticals Inc. Date of Preparation: 130 East Drive February 09, 2022 Brampton, ON L6T 1C1 Submission Control No.: 253642 _ _ _Taro-Calcipotriol / Betamethasone Gel _ _ _ _ _ _ _ _ _ _ _ _Page 2 of 45 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS....................................................................................................8 DRUG INTERACTIONS ..................................................................................................13 DOSAGE AND ADMINISTRATION ..............................................................................14 OVERDOSAGE ................................................................................................................15 ACTION AND CLINICAL PHARMACOLOGY ............................................................15 STORAGE AND STABILITY ..........................................................................................18 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................18 PART II: SCIENTIFIC INFORMATION ............................................................................... 19 PHARMACEUTICAL INFORMATION............................ Read the complete document